Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Susanne Velasco"'
Autor:
Michelle S. Ginsberg, Ana M. Molina, Sujata Patil, Xiaoyu Jia, Robert J. Motzer, James J. Hsieh, Darren R. Feldman, Susanne Velasco
Publikováno v:
Clinical Genitourinary Cancer. 11:297-302
Background Sunitinib achieves objective response and prolongs progression-free survival (PFS) in patients with metastatic renal cell carcinoma (RCC). A subset of patients achieves long-term responses. The characteristics of patients who achieved long
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0d9baa2e5c65069c4a859f73f2e20ee1
https://doi.org/10.1016/j.clgc.2013.04.001
https://doi.org/10.1016/j.clgc.2013.04.001
Autor:
Michelle S. Ginsberg, Carlos D. Flombaum, Hani Hassoun, Patricia Fischer, Sujata Patil, Susanne Velasco, Michael Baum, Ellen A. Ronnen, Robert J. Motzer, Darren R. Feldman, Nicole Ishill
Publikováno v:
Journal of Clinical Oncology. 27:1432-1439
Purpose Both bevacizumab and sunitinib target the vascular endothelial growth factor pathway and demonstrate activity against advanced renal cell carcinoma (RCC). In this phase I study, the maximum-tolerated dose (MTD) and safety of sunitinib in comb
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5dbf47a47e2d14af675f8b2ef596447b
https://doi.org/10.1200/jco.2008.19.0108
https://doi.org/10.1200/jco.2008.19.0108
Autor:
Diogo Assed Bastos, Ana M. Molina, Xiaoyu Jia, Susanne Velasco, Sujata Patil, Martin Henner Voss, Darren Richard Feldman, Robert John Motzer
Publikováno v:
Journal of Clinical Oncology. 32:497-497
497 Background: Brain metastases (Bm) in RCC are associated with poor prognosis. The safety and efficacy of TT in this setting is not well established since patients (pts) with Bm were excluded from pivotal clinical trials. The primary objective was
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::521bae28739b74d5eb86f38439e1d324
https://doi.org/10.1200/jco.2014.32.4_suppl.497
https://doi.org/10.1200/jco.2014.32.4_suppl.497
Autor:
Darren R. Feldman, Diogo Assed Bastos, Xiaoyu Jia, Sujata Patil, Martin H. Voss, Ana M. Molina, Susanne Velasco, Robert J. Motzer
Publikováno v:
Journal of Clinical Oncology. 31:e15517-e15517
e15517 Background: Brain metastases (b-met) in RCC are associated with poor prognosis and median OS of about 7 months in the pre-targeted therapy (TT) era (Culine, Cancer 1998). The role of TT in this setting is not well established since patients (p
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3bc0f3cbb077c688fa7124d70f58f0ef
https://doi.org/10.1200/jco.2013.31.15_suppl.e15517
https://doi.org/10.1200/jco.2013.31.15_suppl.e15517
Autor:
Robert J. Motzer, Xiaoyu Jia, Susanne Velasco, Ana M. Molina, Michelle S. Ginsberg, S. Patil, Darren R. Feldman
Publikováno v:
Journal of Clinical Oncology. 29:4615-4615
4615 Background: Sunitinib has significant activity in pts with mRCC. We report long-term responders, defined as pts achieving ongoing complete response (CR) or remaining progression-free for > 18 ...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d48567f12db35bd69e9e2df8899b4b6d
https://doi.org/10.1200/jco.2011.29.15_suppl.4615
https://doi.org/10.1200/jco.2011.29.15_suppl.4615
Autor:
Susanne Velasco, Darren R. Feldman, Michelle S. Ginsberg, Hani Hassoun, Patricia Fischer, Ellen A. Ronnen, Robert J. Motzer, Michael S. Baum, Nicole Ishill, Carlos D. Flombaum
Publikováno v:
Journal of Clinical Oncology. 26:5100-5100
5100 Background: Bevacizumab and sunitinib both have activity in metastatic renal cell carcinoma (mRCC). Combining bevacizumab and sunitinib may increase antitumor efficacy by maximizing inhibition of the VEGF pathway. The safety and maximum tolerate
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f49e80c592cfdc6ca911b49a7796edfc
https://doi.org/10.1200/jco.2008.26.15_suppl.5100
https://doi.org/10.1200/jco.2008.26.15_suppl.5100